TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention for Improving Psychological Distress in Dialysis (iDiD) Feasibility Two Arm Randomised Controlled Trial: Online Cognitive Behavioural Therapy (CBT) Intervention With Therapist Support vs Online CBT Intervention Alone (no Therapist Support)
Brief Summary: To explore whether it is feasible to recruit and retain haemodialysis patients into a randomised controlled trial of online cognitive-behavioural therapy to manage distress


Options:
A: Arm Label: SystemCHANGE; Type: EXPERIMENTAL; Interventions: Behavioral: SystemCHANGE | Arm Label: Patient-education attention-control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient-education attention control | Intervention Type: BEHAVIORAL; Name: SystemCHANGE; Assigned to Arm(s): SystemCHANGE | Intervention Type: BEHAVIORAL; Name: Patient-education attention control; Assigned to Arm(s): Patient-education attention-control
B: Arm Label: Inform Me: web-based education tool; Type: EXPERIMENTAL; Interventions: Behavioral: Inform Me: web-based education tool | Arm Label: Control Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Inform Me: web-based education tool; Assigned to Arm(s): Inform Me: web-based education tool
C: Arm Label: Multi-component Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action-focused problem-solving, Device: Electronic pillbox monitoring, dose reminders, and feedback | Arm Label: Attention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Action-focused problem-solving; Assigned to Arm(s): Multi-component Intervention | Intervention Type: DEVICE; Name: Electronic pillbox monitoring, dose reminders, and feedback; Assigned to Arm(s): Multi-component Intervention
D: Arm Label: Computerised CBT with therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy, Behavioral: Telephone support | Arm Label: Computerised CBT without therapist support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy | Intervention Type: BEHAVIORAL; Name: Computerised Cognitive Behavioural Therapy; Assigned to Arm(s): Computerised CBT with therapist support, Computerised CBT without therapist support | Intervention Type: BEHAVIORAL; Name: Telephone support; Assigned to Arm(s): Computerised CBT with therapist support

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Protein Intake on Preterm Infant Body Composition
Brief Summary: The investigators will compare weight gain based on fat accretion and change in body composition in preterm infants receiving different amounts of enteral protein.


Options:
A: Arm Label: Intervention group; Type: OTHER; Interventions: Dietary Supplement: Addition of human milk fortifiers according to human milk analysis | Intervention Type: DIETARY_SUPPLEMENT; Name: Addition of human milk fortifiers according to human milk analysis; Assigned to Arm(s): Intervention group
B: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
C: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group
D: Arm Label: Study Human Milk Fortifier A; Type: ACTIVE_COMPARATOR; Interventions: Other: Human Milk Fortifier A | Arm Label: Study Human Milk Fortifier B; Type: EXPERIMENTAL; Interventions: Other: Human Milk Fortifier B | Intervention Type: OTHER; Name: Human Milk Fortifier A; Assigned to Arm(s): Study Human Milk Fortifier A | Intervention Type: OTHER; Name: Human Milk Fortifier B; Assigned to Arm(s): Study Human Milk Fortifier B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Protein Intake on Preterm Infant Body Composition
Brief Summary: The investigators will compare weight gain based on fat accretion and change in body composition in preterm infants receiving different amounts of enteral protein.


Options:
A: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group
B: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
C: Arm Label: Experimental Human Milk Fortifier; Type: EXPERIMENTAL; Interventions: Other: Experimental human milk fortifier | Arm Label: Control Human Milk Fortifier; Type: ACTIVE_COMPARATOR; Interventions: Other: Control human milk fortifier | Intervention Type: OTHER; Name: Experimental human milk fortifier; Assigned to Arm(s): Experimental Human Milk Fortifier | Intervention Type: OTHER; Name: Control human milk fortifier; Assigned to Arm(s): Control Human Milk Fortifier
D: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders
Brief Summary: Specific Aim 1: Obtain proof of concept evidence that cortical metrics will change in response to treatment with Memantine extended release (XR)®, an agent that modulates n-methyl d-asptartate (NMDA) receptor activation, in children with autism spectrum disorders (ASD) who clinically demonstrate treatment response.

Hypothesis1: Children with ASD who have dramatic clinical response to Memantine XR® will exhibit changes in their cortical metrics, which will differ less from neurotypical children. Subjective ratings of improvement will be correlated with the change in cortical metrics.

The completion of these aims will be essential to design a larger federally funded trial to validate cortical metrics as an outcome measure in a more heterogeneous pediatric ASD sample. Specifically, the feasibility data obtained may demonstrate the potential for detecting changes in cortical metrics over time, so that a larger grant could focus on determining how sensitive and clinically relevant changes in cortical metrics are or may indicate the need to explore different interventions to use in a validation study. We have chosen to use Memantine XR® because of its impact on NMDA neurotransmission, its current evaluation in a large multi-site randomized ASD clinical trial whose initial results are expected shortly, and our own observations of clinical improvements and good tolerability in the ongoing trial.


Options:
A: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine
B: Arm Label: Memantine-XR; Type: N/A; Interventions: Drug: Memantine-XR | Intervention Type: DRUG; Name: Memantine-XR; Assigned to Arm(s): Memantine-XR
C: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomised Control Trial of Blastocyst Euploidy Assessment and Conditioned Embryo Transfer for Infertility Patients of Advanced Maternal Age
Brief Summary: The study is designed to evaluate the effectiveness of pre-implantation genetic screening (PGS) for infertility patients of advanced maternal age undergoing assisted reproductive treatment. Half of the patients will have their embryos tested by PGS and 1 or 2 chromosomally normal embryos with the highest morphological grading transplanted back to the uterus. The other half of the participants will not have their embryos tested and 1 or 2 untested embryos with the highest morphological grading transplanted back to the uterus.


Options:
A: Arm Label: Control - Standard ART treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test - PGS; Type: EXPERIMENTAL; Interventions: Genetic: Next Generation Sequencing after Blastocyst biopsy | Intervention Type: GENETIC; Name: Next Generation Sequencing after Blastocyst biopsy; Assigned to Arm(s): Test - PGS
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: PGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PGS; Assigned to Arm(s): Group A
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A
D: Arm Label: Endometrial injury group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial injury | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Endometrial injury; Assigned to Arm(s): Endometrial injury group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Low Glycemic Index Mediterranean Diet on AGEs. A Randomized Clinical Trial
Brief Summary: Advanced glycation end products (AGE) result from a chemical reaction between the carbonyl group of reducing sugar and the nucleophilic NH2 of a free amino acid or a protein; lysine and arginine being the main reactive amino acids on proteins. Following this first step, a molecular rearrangement occurs, rearrangement of Amadori resulting to the formation of Maillard products.


Options:
A: Arm Label: Diet: Dietary Advice; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: General Advice | Arm Label: Low glycemic index Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low Glycemic Index Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Low Glycemic Index Mediterranean Diet; Assigned to Arm(s): Low glycemic index Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: General Advice; Assigned to Arm(s): Diet: Dietary Advice
B: Arm Label: Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Other: mediterranean diet | Arm Label: normocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Other: normocaloric diet | Intervention Type: OTHER; Name: mediterranean diet; Assigned to Arm(s): Mediterranean Diet | Intervention Type: OTHER; Name: normocaloric diet; Assigned to Arm(s): normocaloric diet
C: Arm Label: INRAM guidelines' diet; Type: PLACEBO_COMPARATOR; Interventions: Other: INRAM Guidelines' diet | Arm Label: Low Glycemic Index Mediterranean Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Glycemic Index Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Low Glycemic Index Mediterranean Diet; Assigned to Arm(s): Low Glycemic Index Mediterranean Diet | Intervention Type: OTHER; Name: INRAM Guidelines' diet; Assigned to Arm(s): INRAM guidelines' diet
D: Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines
Brief Summary: The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG)), used for the improvement in the appearance of moderate to severe glabellar lines (the lines between the eyebrows).


Options:
A: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo
B: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo
C: Arm Label: Dose A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose B; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose C; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose D; Type: ACTIVE_COMPARATOR; Interventions: Biological: Active Comparator botulinum toxin | Arm Label: Dose E; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Comparator | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): Dose A, Dose B, Dose C | Intervention Type: BIOLOGICAL; Name: Active Comparator botulinum toxin; Assigned to Arm(s): Dose D | Intervention Type: BIOLOGICAL; Name: Placebo Comparator; Assigned to Arm(s): Dose E
D: Arm Label: BTX-A-HAC NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): BTX-A-HAC NG | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using a Tailored Health Information Technology Driven Intervention to Improve Health Literacy and Medication Adherence in a Pakistani Population With Vascular Disease
Brief Summary: Although most patients admitted with acute coronary syndrome or acute ischemic stroke in South Asian countries receive these evidence-based treatments, their overall continuation in the outpatient phase of care remains low. Patient from Pakistan are uniquely challenged in this respect because the overall literacy rates remain one of the lowest in Pakistan among South Asian Countries. In addition, a great majority of Pakistani patients often do not understand or follow health prescriptions (which are still written in English). Additionally, due to an unregulated health industry, they frequently take multiple opinions and prescriptions from different physicians. The investigators propose to develop a "talking prescription" for patients with stroke or myocardial infarction for secondary prevention. This will enable them to understand their medications better, improve health literacy and adherence. This is an IT enabled health literacy intervention. Physicians will prescribe statin and/or antiplatelet to the selected patients and enter the necessary details on an Optical Mark Recognition (OMR) sheet.Patients will be assigned to either of the 2 arms--either regular care or talking prescriptions. Follow-up will be done at 3 months post recruitment for behavioral knowledge assessment and adherence assessment.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: HITCM+CP | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HITCM only | Intervention Type: BEHAVIORAL; Name: HITCM+CP; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: HITCM only; Assigned to Arm(s): Arm 2
B: Arm Label: SMS Short Message Service Arm plus Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: SMS- Short Messaging Service | Arm Label: Standard Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS- Short Messaging Service; Assigned to Arm(s): SMS Short Message Service Arm plus Prescription
C: Arm Label: text message medication reminders; Type: EXPERIMENTAL; Interventions: Behavioral: text message medication reminders | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text message medication reminders; Assigned to Arm(s): text message medication reminders
D: Arm Label: Talking Rx; Type: EXPERIMENTAL; Interventions: Behavioral: Talking Rx | Arm Label: Usual Care, Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Talking Rx; Assigned to Arm(s): Talking Rx

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.
Brief Summary: Part 1 (Phase 1): safety and tolerability of bevacizumab-Niraparib combination Part 2 (Randomized Phase 2): to compare Progression-Free Survival (PFS)

PARP inhibitors are active as monotherapy to treat patients with recurrent ovarian cancer; the strongest activity being observed in the platinum sensitive, gBRCAmut subgroup as well as in gBRCAwt, HRD population but also in HRD negative disease.

In the same population there is level one evidence that bevacizumab is beneficial. And a phase two randomized study has indicated that combination of a PARP inhibitor with anti-angiogenic drug is superior to PARP inhibitor alone.

The question is:

Is niraparib combined with bevacizumab superior to niraparib? The comparison of tolerability and efficacy of niraparib-bevacizumab combination against niraparib.


Options:
A: Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept
B: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1
D: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination

Answer: D